Short-Term Efficacy of Transcranial Focused Ultrasound to the Hippocampus in Alzheimer's Disease: A Preliminary Study

• Published in: Journal of personalized medicine Vol. 12; no. 2; p. 250
• Main Authors: Jeong, Hyeonseok, Song, In-Uk, Chung, Yong-An, Park, Jong-Sik, Na, Seung-Hee, Im, Jooyeon Jamie, Bikson, Marom, Lee, Wonhye, Yoo, Seung-Schik
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 09.02.2022; MDPI
• Subjects: Alzheimer's disease; Blood-brain barrier; Brain research; Clinical trials; cognition; Cognition & reasoning; Cognitive ability; Contrast agents; Contrast media; Deoxyglucose; Hippocampus; Image processing; Intravenous administration; Magnetic resonance imaging; Memory; Mental disorders; Metabolic rate; Neurodegenerative diseases; Neuroimaging; Neuropsychology; Outpatient care facilities; Patients; Positron emission tomography; Precision medicine; regional cerebral metabolic rate of glucose; Sonication; Tomography; transcranial focused ultrasound; Ultrasonic imaging; Ultrasound; United States > US; blood–brain barrier; regional cerebral metabolic rate of glucose; Alzheimer’s disease; cognition; transcranial focused ultrasound
• ISSN: 2075-4426; 2075-4426
• DOI: 10.3390/jpm12020250

Preclinical studies have suggested that low-intensity transcranial focused ultrasound (tFUS) may have therapeutic potential for Alzheimer's disease (AD) by opening the blood-brain barrier (BBB), reducing amyloid pathology, and improving cognition. This study investigated the effects of tFUS on BBB opening, regional cerebral metabolic rate of glucose (rCMRglu), and cognitive function in AD patients. Eight patients with AD received image-guided tFUS to the right hippocampus immediately after intravenous injection of microbubble ultrasound contrast agents. Patients completed magnetic resonance imaging (MRI), F-fluoro-2-deoxyglucose positron emission tomography (PET), and cognitive assessments before and after the sonication. No evidence of transient BBB opening was found on T1 dynamic contrast-enhanced MRI. However, immediate recall ( = 0.03) and recognition memory ( = 0.02) were significantly improved on the verbal learning test. PET image analysis demonstrated increased rCMRglu in the right hippocampus ( = 0.001). In addition, increases of hippocampal rCMRglu were correlated with improvement in recognition memory (Spearman's = 0.77, = 0.02). No adverse event was observed. Our results suggest that tFUS to the hippocampus of AD patients may improve rCMRglu of the target area and memory in the short term, even without BBB opening. Further larger sham-controlled trials with loger follow-up are warranted to evaluate the efficacy and safety of tFUS in patients with AD.